Expleo Solutions Q2 FY27 Results & Earnings Intelligence
EXPLEOSOLStructural risk assessment following Q2-FY27 | 30 Sep 26 earnings.
₹292.6 Cr
Reported
₹46.2 Cr
-10.1% YoY•+4.4% QoQ
₹36.4 Cr
-8.5% YoY•+6.5% QoQ
34/ 100
+18 pts QoQ
The Quarter at a Glance
Consolidated Financials| Metric | Q2-FY27 | 30 Sep 26 | Q2-FY26 | 30 Sep 25 | YoY Δ | Q1-FY27 | 30 Jun 26 | QoQ Δ |
|---|---|---|---|---|---|
| Revenue from Operations | ₹292.6 Cr | N/A | N/A | N/A | N/A |
| Revenue (Total Income) | ₹302.6 Cr | ₹295.4 Cr | +2.4% | ₹298.5 Cr | +1.4% |
| Operating Profit (EBITDA) | ₹46.2 Cr | ₹51.4 Cr | -10.1% | ₹44.2 Cr | +4.4% |
| Profit Before Tax (PBT) | ₹46.2 Cr | ₹51.4 Cr | -10.1% | ₹44.2 Cr | +4.4% |
| EBIT Margin | 15.27% | 17.39% | -212 bps | 14.82% | +45 bps |
| Net Profit (PAT) | ₹36.4 Cr | ₹39.8 Cr | -8.5% | ₹34.2 Cr | +6.5% |
| Interest Expense | ₹0.5 Cr | ₹0.6 Cr | -14.5% | ₹1.2 Cr | -55.9% |
| Operating Cash Flow | ₹65.7 Cr | ₹75.6 Cr | -13.2% | N/A | N/A |
| Basic EPS (₹/share) | ₹23.45 | N/A | N/A | N/A | N/A |
Sources:Official BSE/NSE Disclosures & Financial Filings
Operating EBIT margin of 15.3% measures employee billing realization, project utilization, and software pricing power against global Tier-1 peers.
Sentinel Executive Summary
AI Forensic Synthesis🚨 Structural Deterioration Signature: In Q2 FY2027, Expleo Solutions reported a 2.4% YoY revenue growth to ₹302.6 Cr, but net profit contracted by 8.5% to ₹36.4 Cr, with EBITDA margins compressing by 3.4 pp to 16.7%. This deterioration persists across interim quarters since FY2026, with Q1 FY2027 showing 12.0% revenue growth and Q2 FY2027 confirming a 2.4% YoY revenue expansion, though net profit remained under sector median performance.
The operational strain is compounded by elevated governance risks, with two board-level resignations in Q2 FY2027, and a cash conversion deficit, though operating cash flow (₹119.5 Cr) has normalized. The company’s zero-debt profile and working capital (trade receivables: ₹229.6 Cr) provide liquidity capacity, but relative growth weakness and governance integrity shocks push the firm into Flagium’s heightened surveillance range.
🟢 Key Operational & Structural Positives
- ✓Revenue Growth: Quarterly revenue moved +2.4% YoY and +1.4% QoQ, reflecting demand and volume trends.
⚠️ Key Areas of Watch & Margin Pressures
- ⚠Resolution of 'Governance Integrity Shock': EXPLEOSOL: Key governance event detected: DIRECTOR_RESIGNATION.
- ⚠Resolution of 'Relative Growth Weakness': Revenue growth consistently lags behind sector median (16.1%).
- ⚠Operating margin pressure: Margin moved -212 bps YoY to 15.3%, monitor overhead and operational cost absorption.
Net Profit (PAT) contracted -8.5% YoY, but rebounded +6.5% QoQ vs Q1-FY27, showing bottom-line recovery momentum.
Flagium Risk Signals
Automated Forensic SignalsGovernance Integrity Shock • Relative Growth Weakness
EXPLEOSOL: Key governance event detected: DIRECTOR_RESIGNATION.
Revenue growth consistently lags behind sector median (16.1%).
🎙️ Expleo Solutions (EXPLEOSOL) Q2 FY27 Concall Intelligence
Management Commentary, Concall Takeaways & Key Discussion Themes
No earnings call transcript was available
for this reporting period.
What to do next
Explore EXPLEOSOL's full structural risk profile — 12Q score trajectory, pillar breakdown, flag history, and peer benchmarking.
View EXPLEOSOL profile →See how Information Technology peers and the broader market are positioned. Identify sector-wide stress or rotation signals.
Open market monitor →Check how this Q2-FY27 | 30 Sep 26 result affects your portfolio's overall risk exposure and concentration.
Review your portfolio →Continue Research
📬 Flagium Risk Brief — Track forensic risks on EXPLEOSOL & 3 market anomalies weekly
See a sample issue →Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE) for educational and research purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.